NewroBus

Carrying Biologics Across the Blood-Brain Barrier

A Novel Approach to Alzheimer’s Disease

NewroBus

Our Mission

Developing novel treatments for Alzheimer’s Disease and other neurodegenerative diseases by carrying powerful biologics across the Blood Brain Barrier (BBB)

Our Technology

Versatile and patented platform based on single-chain nanobodies exploiting Transferrin Receptor 1 (TfR1) mediated transcytosis to carry biologics efficiently and safely across the BBB.

NewroBus

Exploiting Transferrin Receptor 1 (TfR1) transcytosis to carry biologics through the BBB

  • High humanness and specificity
  • High BBB permeability (CSF/Serum ratio >0.90)
  • High tolerability
Mechanism of Action
Alzheimer-disease

Alzheimer Disease and TNF-α

Tumor necrosis factor α (TNF-α) plays a central role in the pathophysiology of Alzheimer’s Disease (AD). FDA–approved biologic TNF-α inhibitors are potential treatments for AD, but they do not cross the blood-brain barrier.

Our Lead Product: NN-841

Heterotrimer consisting of NewroBus NN-103 linked to two molecule of TNF-α inhibitors tested in animals

  • NN-841 crosses the BBB after subcutaneous administration
  • High CSF/Serum ratio and broad brain distribution
  • Potent TNF-α inhibition
  • Excellent tolerability
Lead Compound

The NanoNewron Team

Marco Taglietti avatar

Marco Taglietti

Chief Executive Officer

Luciano Dadamio Avatar

Luciano D'Adamio

Founder & Chief Scientific Officer

Peter Golikov avatar

Peter Golikov

Chief Operating Officer

Scroll to Top